AZNAstraZenecaRunning, no new patients
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
Breast Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 1,902 (final count)
- Started
- Nov 14, 2023
- Main results expected
- Nov 20, 2028
- Fully finished
- Sep 23, 2032
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Event-free survival (EFS) in the experimental vs control arms
Measured over: Date of randomization to date of the EFS event, up to 93 months after the first subject randomized
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06112379 · record last updated 2026-10-21 · checked 2026-11-09 15:47 UTC